Please assess the completion status of the following clinical trial:

Trial Title: Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Arteriographically confirmed acute PAO of the lower extremity with onset of symptoms within 14 days prior to randomization~* Acute index limb ischemia classified as SVS/ISCVS Class I or IIa caused by occlusion of a native artery and/or bypass graft (vein or prosthetic). Only Class I subjects with abrupt onset of ischemic rest pain or abrupt onset/progression of lifestyle-limiting claudication are eligible~* Acute PAO with a need for urgent surgical intervention to restore arterial blood flow in the event of unsuccessful thrombolytic therapy~* Available for follow-up assessments~Exclusion Criteria:~* Contraindication to systemic anticoagulation~* History of endovascular procedure or open vascular surgery on the index limb within the past 30 days~* History of significant acute or chronic kidney disease that would preclude contrast angiography~* Known allergy to contrast agents~* History of heparin induced thrombocytopenia~* Participation in any study of an investigational device, medication, biologic, or other agent within 30 days prior to randomization~* Any thrombolytic therapy within 5 days prior to randomization~* Past participation in any alfimeprase trial~* Pregnant, lactating, or actively menstruating women or women of childbearing potential who are not using adequate contraceptive precautions~* Investigator inability to advance guidewire through index occlusion~* Any other subject feature that in the opinion of the investigator should preclude study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).